Maximizing binary interactome mapping with a minimal number of assays by Choi, S.G. et al.
ARTICLE
Maximizing binary interactome mapping with a
minimal number of assays
Soon Gang Choi 1,2,3,14, Julien Olivet 1,2,3,4,14, Patricia Cassonnet5,14, Pierre-Olivier Vidalain6,14,
Katja Luck 1,2,3, Luke Lambourne 1,2,3, Kerstin Spirohn 1,2,3, Irma Lemmens7,8, Mélanie Dos Santos5,
Caroline Demeret 5, Louis Jones9, Sudharshan Rangarajan1,2,3, Wenting Bian1,2,3, Eloi P. Coutant 10,
Yves L. Janin 10, Sylvie van der Werf 5, Philipp Trepte 11,12, Erich E. Wanker 11, Javier De Las Rivas 13,
Jan Tavernier7,8, Jean-Claude Twizere 4, Tong Hao 1,2,3, David E. Hill 1,2,3, Marc Vidal1,2,
Michael A. Calderwood 1,2,3 & Yves Jacob 1,5
Complementary assays are required to comprehensively map complex biological entities
such as genomes, proteomes and interactome networks. However, how various assays can
be optimally combined to approach completeness while maintaining high precision often
remains unclear. Here, we propose a framework for binary protein-protein interaction (PPI)
mapping based on optimally combining assays and/or assay versions to maximize detection
of true positive interactions, while avoiding detection of random protein pairs. We have
engineered a novel NanoLuc two-hybrid (N2H) system that integrates 12 different versions,
differing by protein expression systems and tagging configurations. The resulting union of
N2H versions recovers as many PPIs as 10 distinct assays combined. Thus, to further improve
PPI mapping, developing alternative versions of existing assays might be as productive as
designing completely new assays. Our findings should be applicable to systematic mapping of
other biological landscapes.
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Complex biological entities such as genomes, proteomes,and interactome networks require multiple, orthogonalapproaches to be fully characterized. Even in the case
of DNA, a highly homogenous macromolecule, sequencing
and assembly of large genomes such as the human genome
requires combinations of complementary methodologies includ-
ing short-read sequencing as those provided by Illumina plat-
forms, long-read DNA sequencing as in PacBio and/or Nanopore
technologies, and HiC-related chromatin mapping tools1.
Because polypeptides are more heterogeneous and structurally
complex macromolecules than DNA2, determining protein fea-
tures at the scale of the whole proteome is considerably more
challenging than characterizing nucleic acid sequences. For
instance, to expand the detectable portion of a proteome by mass-
spectrometry, negative peptide ionization approaches are neces-
sary to complement canonical positive-mode strategies3. Another
example is protein crystallization that often requires hundreds of
different conditions to be tested, including combining parameters
such as ionic strength, temperature, pH, salt, protein concentra-
tions, and others4. Structural proteomics, which determines
protein structures at proteome-scale5 also requires a palette of
technologies such as X-ray crystallography, nuclear magnetic
resonance (NMR), and/or cryogenic electron microscopy (cryo-
EM) to reasonably cover proteins and protein complexes of dif-
ferent sizes, solubilities, and flexibilities6,7.
In short, the mapping of large macromolecular landscapes
usually requires multiple technologies that can be combined to
complement each other’s relative shortcomings. However, for
most comprehensive mapping projects, it remains unknown how
to optimally combine various experimental methods in order to
achieve maximal detection and specificity by a minimal number
of assays.
Macromolecules including DNA, RNA, and proteins do not
work in isolation but assemble into molecular machines, signaling
cascades and metabolic pathways through interactions with other
macromolecules, altogether forming complex interactome net-
works that are critical for biological systems8,9. As
protein–protein interactions (PPIs) play a pivotal role in these
networks, it is essential to comprehensively identify binary
PPIs10–12 and co-complex protein associations13–15, both at the
scale of signaling pathways16,17, molecular machines18,19 and
network modules20, and at the scale of the whole proteome12.
Although medium- to high-throughput binary PPI detection
assays have been available for three decades, since the original
description of the yeast two-hybrid (Y2H) system21, it remains
impossible to completely map interactome networks using any
assay in isolation. This is well illustrated by the fact that most
binary PPI assays developed so far only detect about a third of
well-described benchmark interactions from a positive reference
set (PRS) under conditions that limit, but not necessarily com-
pletely prevent, the detection of negative control protein pairs
from a random reference set (RRS)22–27. However, since different
assays23 or assay versions28,29 often detect overlapping, yet dis-
tinct subsets of interactions, combining them should significantly
increase overall detection.
In order to comprehensively map binary PPIs both at the scale
of signaling pathways and protein complexes and at the scale of
whole proteomes, it should thus be possible to establish an
optimal combination of assays and/or assay versions to capture
nearly all interactions in a defined search space while ensuring
high specificity (Fig. 1a). Our goal here was to systematically
analyze experimental variables that influence binary PPI detection
across multiple assays, and integrate such knowledge into the
rational design of a binary PPI detection framework involving a
minimal number of assays with maximal recovery.
We evaluated a class of binary PPI assays that are based on
exogenously expressing pairs of hybrid proteins, collectively
referred to as Tag1-X and Tag2-Y, where X and Y can be any
protein, and Tag1 and Tag2 are two polypeptidic moieties, the
physical proximity of which can be readily monitored. For
example, in the Y2H system, X and Y interacting proteins restore
physical proximity between the DNA binding domain (DB) and
the activation domain (AD) of a transcription factor upon exo-
genous expression of DB-X and AD-Y hybrid proteins21,30.
In addition to assessing different assays defined by specific tag
pairs, we also evaluated assay version differences due to: (i) the
relative orientation or swap of the tested proteins X and Y, dif-
ferentiating between Tag1-X/Tag2-Y and Tag1-Y/Tag2-X; (ii) the
tagging configurations where we distinguish protein fusions from
either the N- or C-terminal extremities of X and Y, e.g. Tag1-X/
Tag2-Y vs. X-Tag1/Y-Tag2; and (iii) the exogenous expression
systems, either in yeast, in mammalian cells, or in vitro (cell-free)
(Fig. 1b).
To uniformly compare these different experimental conditions
within a single assay, we have engineered a PPI detection tech-
nology based on the functional reconstitution of NanoLuc, a
small 19 kDa, high-performance bioluminescent protein31. Using
this NanoLuc two-hybrid (N2H) system in combination with
highly versatile vectors capable of driving protein expression as
N- or C-terminal fusions of assay tags in all three environments,
we show that permuting various experimental conditions in a
single assay can achieve similar PPI detection as through
the continuous addition of fundamentally different techniques
(Fig. 1c). Our results suggest that only a few versatile assays
should be sufficient to achieve near saturation with maximal
precision in medium- and high-throughput proteome-scale PPI
mapping projects. This finding might also be of value for large-
scale mapping of other complex biological landscapes.
Results
Combining binary PPI assays under maximized specificity.
Different binary PPI assays often detect distinct subsets of
interactions23, thus combining several assays should increase the
overall recovery in a given search space of the proteome (Fig. 1a).
However, what remains unclear is how binary PPI assay combi-
nations affect the overall specificity, i.e. the fraction of true
interactions detected in a given search space over the fraction of
spurious pairs reported.
Ten years ago, our group introduced an empirical framework to
benchmark binary PPI assays based on: (i) a list of ~100 well-
documented positive control PPIs, constituting the first version of
a PRS, or hsPRS-v1, (ii) a list of ~100 pairs of proteins randomly
picked among the ~2 x 108 pairwise combinations of human
proteins, constituting version 1 of a RRS, or hsRRS-v1;22 and (iii)
the Gateway cloning of all open reading frames (ORFs) involved,
allowing identical constructs to be used across many different
assays32. We and others have since cross-examined the following
binary PPI assays against each other: (i) Y2H23, (ii) yellow
fluorescent protein–protein complementation assay (YFP-PCA)23,
(iii) mammalian protein–protein interaction trap (MAPPIT)23,
(iv) well-based nucleic acid programmable protein arrays
(wNAPPA)23, (v) luminescence-based mammalian interactome
(LUMIER)23, (vi) kinase substrate sensor (KISS)25, (vii) Gaussia
princeps complementation assay (GPCA)24,33, (viii) dual
luminescence-based co-immunoprecipitation (DULIP)26, and
(ix) bioluminescence-based two-hybrid (LuTHy)27, combining
bioluminescence resonance energy transfer (LuTHy-BRET) and
luminescence-based co-precipitation (LuTHy-LuC) assays (Fig. 1c,
left panel).
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Under the various conditions used in these studies, each of the
corresponding 10 assays, representing the union of only one or
two version(s) (Supplementary Table 1), recovered between 21
and 39% of hsPRS-v1 pairs, with the negative control hsRRS-v1
detection ranging between 0 and 4% (Supplementary Fig. 1a).
However, to directly compare the different assays side-by-side
and combine them homogeneously, an identical RRS threshold
should be applied to each individual assay. After applying an
identical RRS cutoff, increasing from 1 to 10%, to each of the
above-mentioned assays, we observed that the union of the ten
different assays detected between 70% and 91% of positive control
hsPRS-v1 pairs with 8% and 59% of random hsRRS-v1 pairs
scoring positive, respectively (Supplementary Fig. 1b). Therefore,
to avoid accumulation of random pairs affecting the quality of
future analyses, each assay should be calibrated such that none of
the RRS pairs are scored positive. After reanalyzing published
data under these conditions, the recovered fractions of hsPRS-v1
pairs ranged from 3 to 33% for individual assays performed in
only one or two version(s) (Fig. 2a), while the cumulative
detection reached 65% when all assays were combined (Fig. 2b
and Supplementary Fig. 1c). This suggested that many different
assays, each associated with specific tag pairs and plasmids, would
be needed to reach full coverage.
Benchmarking binary PPI assays and assay versions. We con-
sidered the possibility that the failure of the 10 assays described
above (Fig. 2a, b) to detect nearly all PRS interactions might be
due to ORF clone quality issues and/or problematic interaction
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annotations. To avoid such possibilities, we re-examined all
protein pairs from the original reference sets: hsPRS-v1 and
hsRRS-v123. As a first step, only fully sequence-verified, full-
length clonal ORFs were isolated (Supplementary Fig. 2a).
Resulting pairs were then filtered based on updated literature
information and annotations for binary PPIs (Supplementary
Table 2, Supplementary Data 1). Finally, 60 PRS and 78 RRS pairs
were assembled into a second-generation of reference sets: hsPRS-
v2 and hsRRS-v2, respectively (see Methods for details and
Supplementary Fig. 2b). After repeating four assays that
were originally benchmarked against hsPRS-v1 and hsRRS-v1
with the second generation of reference sets, the cumulative
PRS recovery rate reached 50 and 58% with -v1 and -v2 sets
respectively, when none of the RRS pairs were scored positive
(Supplementary Fig. 2c).
As the failure of 10 well-established assays to detect nearly all
binary PPIs did not arise from problems with the original
reference sets, we decided to evaluate whether expanding the
number of experimental conditions, or assay versions (Fig. 1b),
covered by any single technique could increase its coverage and
ultimately reduce the number of assays required. To investigate
this, we benchmarked several versions of Y2H, MAPPIT, KISS,
and GPCA against the second-generation of reference sets,
hsPRS-v2 and hsRRS-v2. These four assays and corresponding
versions (10 in total) were implemented as summarized in
Supplementary Table 1. In particular, we constructed Gateway-
compatible vectors for GPCA to cover all four possibilities of
tagging configurations with this assay, i.e. Tag1-X/Tag2-Y, X-
Tag1/Tag2-Y, Tag1-X/Y-Tag2, and X-Tag1/Y-Tag2 or, simply,
N1N2, C1N2, N1C2, and C1C2, respectively. Between 8 and 37%
of hsPRS-v2 pairs were detected by the 10 versions of GPCA,
MAPPIT, KISS and Y2H when none of the hsRRS-v2 pairs were
scored positive (Fig. 2c), which represented an average PRS
detection rate of 22.8 ± 8.8% (S.D.) (Fig. 2c, shaded blue area).
When we considered all protein pairs identified by the union of
these 10 versions corresponding to four assays, the hsPRS-v2
recovery rate reached 63% (Fig. 2d and Supplementary Fig. 2d),
similar to what was obtained by combining ten distinct assays,
performed in only one or two version(s), as published in the
literature (65%; Fig. 2b). This result demonstrates that the
combination of four distinct assays exploring different experi-
mental conditions can recover as many PPIs as 10 fundamentally
different techniques limited to a few versions.
Toward developing a highly versatile binary PPI assay. In an
attempt to further minimize the overall number of multi-version
assays required to maximize binary PPI detection and, by
extension, reduce the associated cloning efforts and lab resources,
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we decided to develop a highly versatile binary PPI detection
system opening access to all assay versions defined by the three
experimental parameters presented in Fig. 1b.
Although after reanalyzing published data, 1.3-fold and 1.4-
fold increases in PRS detection were observed when switching
from one orientation to the other (i.e. Tag1-X/Tag2-Y to Tag1-Y/
Tag2-X), or from one configuration to another (i.e. N1N2 to
C1N2), respectively (Supplementary Fig. 3a, b), the impact of
permuting expression systems remained unclear as no assay had
been used to systematically explore this parameter. However,
several high-quality PPI datasets have been obtained using
heterologous expression of protein pairs in yeast12,34, in
mammalian cells35,36 and via cell-free coupled transcription-
translation systems in vitro37,38.
After surveying existing binary interaction assays, it appeared
that split-protein reconstitution was the most suitable technology
to cover the three experimental parameters presented in Fig. 1b.
Indeed, compared to other binary PPI methods involving cell-
specific responses or antibody-based captures, split-protein-based
assays enable detection of PPIs through the simple reassembly of
a functional reporter protein (Fig. 1c). Among the different
reporters available today, NanoLuc, a highly stable 19 kDa protein
derived from the luciferase complex of the deep-sea shrimp O.
gracilirostris, is gaining increasing attention for the development
of binary PPI detection assays, as highlighted by recent
publications31,39–41. Following the single-step addition of imida-
zopyrazinone substrates, NanoLuc instantly produces an intense
and sustainable glow-type luminescence with a specific activity
about 100-fold greater than that of other luciferases, allowing its
detection in vitro as well as in living cells and animals31,42,43.
Therefore, split-NanoLuc-based technology appears to be the
ideal candidate for the high-throughput detection of binary PPIs
under various experimental conditions.
Among the recent studies reporting a split-NanoLuc binary
PPI assay, only one extensively fragmented the enzyme to test
different tag pairs in an unbiased way (Supplementary Table 3)39.
After selecting a cleavage site between amino acids 156 and 157,
the authors heavily modified the corresponding fragments to
reduce their association affinity. The resulting moieties, 11S (156
amino acids) and 114 (11 amino acids), were then used to develop
the NanoLuc Binary Technology (NanoBiT) assay39.
Although NanoBiT was originally designed for expression of
protein pairs in mammalian cells, we decided to evaluate whether
fragments 11S and 114 could be used to further develop our new,
highly versatile binary PPI detection system (Fig. 1c, right panel).
To investigate this, we first adapted the available NanoBiT vectors
with the reported original split site39 to achieve different tagging
configurations with Gateway-cloning compatibility and then
benchmarked all four pairing combinations, i.e. N1N2, C1N2,
N1C2, and C1C2, against hsPRS-v2 and hsRRS-v2. The
benchmarking of these four NanoBiT versions in conditions
where none of the hsRRS-v2 pairs are scored positive showed that
between 3 and 25% of hsPRS-v2 pairs could be recovered (Fig.
2c). These results revealed optimal performances when the larger
NanoBiT fragment, 11S (156 amino acids), was fused to the C-
terminal extremity of the tested proteins, as demonstrated by PRS
recovery rates of 22% and 25% for the C1N2 and C1C2
configurations, respectively, similar to those from four other
well-established assays (Fig. 2c). These observations were in
agreement with the author’s original assumption that the C-
terminus tagging of proteins with 11S might impose minimal
steric constraints39.
Nanoluc 2-Hybrid (N2H): a highly versatile binary PPI assay.
Although NanoBiT appears to be a powerful tool to study PPI
kinetics in live cells, the comprehensive benchmarking of this
assay revealed two underperforming versions, N1N2 and N1C2,
that might be associated with the inherent properties of the
selected tag pair39. Therefore, we decided to empirically define a
new split site for NanoLuc in an unbiased way. To do this, we
first extensively fragmented the full-length enzyme by
transposon-based insertional mutagenesis (Supplementary Fig.
4a). Complementation of the resulting fragments, F1 and F2 (58
pairs in total), was then systematically tested using a proximity
assay in vitro (Supplementary Fig. 4b), and a cleavage
site between amino acids 65 and 66 was selected (Fig. 3a) to
build the NanoLuc 2-hybrid (N2H) assay (Fig. 1c, right panel;
Supplementary Fig. 4c).
In order to comprehensively cover the experimental para-
meters presented in Fig. 1b with the single N2H assay, we
constructed four Gateway-compatible plasmids from which N2H
fragments, F1 (amino acids 1–65) and F2 (amino acids 66–171),
can be expressed as either N- or C-terminal fusions of any pair of
proteins X and Y in yeast, in mammalian cells or in vitro (cell-
free). To drive expression in all three environments with each
individual plasmid, we engineered a tripartite promoter of ~1 kb
that can easily be introduced into any vector of interest (Fig. 3b).
The performance of this 3-in-1 promoter was evaluated by
measuring the expression of full-length and fragmented NanoLuc
in yeast (yN2H), in mammalian cells (mN2H) and in vitro
(vN2H). We obtained intense signals ranging between 108 and
109 relative luminescence units (RLU) when the full-length
NanoLuc was expressed in each individual environment.
Furthermore, compared to the full-length enzyme, individually
expressed NanoLuc fragments did not produce any significant
signal. More importantly, the two fragments expressed together
did not generate any strong self-assembly luminescence that
could interfere with the accurate measurement of binary PPIs.
Taken together, these results demonstrate the full functionality of
both the tripartite promoter and the selected pair of NanoLuc
fragments (Fig. 3b).
By combining NanoLuc fragments with the tripartite promoter
and the Gateway-cloning technology into four uniform expres-
sion vectors (pDEST-N2H-N1, -N2, -C1, and -C2), all 24 assay
versions (4x3x2) presented in Fig. 1b can thus be implemented
with the single N2H assay. The Gateway-compatibility of N2H
destination plasmids also renders the entire human ORFeome
collection of over 18,000 entry clones44 directly amenable to
this assay.
As N2H was the first binary PPI detection tool in which
proteins could be expressed as either N- or C-terminal fusions of
protein tags in yeast (yN2H), in mammalian cells (mN2H) or
in vitro (vN2H) from the same Gateway-compatible destination
vector (Figs. 1b, c, 3b), it was important to benchmark the
robustness of PPI-mediated readouts in each of the three
environments. Using hsPRS-v2 and hsRRS-v2 pairs, we compared
bioluminescence signals between two independently replicated
experiments in yN2H, mN2H, and vN2H. As highlighted by the
R2 > 0.97, a robust reproducibility was observed in each case
when all 138 pairs from hsPRS-v2 and hsRRS-v2 were tested. In
addition, a large dynamic range of luminescence readout, between
102 and 107 RLU, was consistently observed in each environment
(Fig. 3c).
To compare the performance of N2H assay versions in
detecting reference binary PPIs over random protein pairs, we
normalized luminescence signals and separated hsPRS-v2 from
hsRRS-v2. No major differences were observed in the overall
luminescence ratios as a fraction of PRS pairs always generated
higher signals than that from random pairs in each case (Fig. 3d).
As observed for C1C2-mN2H or C1C2-yN2H, for example, the
only differences in PRS detection rates between assay versions
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came from one or a few RRS pairs that generated higher
luminescence signals than the average. These version-specific
artifacts ultimately reduced the fraction of PRS pairs recovered as
their corresponding thresholds of no RRS pair scoring positive
increased (Fig. 3d). The same observation was also made for well-
established assays (Fig. 2a, c). Thus, in conditions where none of
the RRS pairs are scored positive (threshold displayed for each
individual version in Fig. 3d), the 12 tested N2H assay versions
detected between 7 and 32% of hsPRS-v2 pairs (Fig. 3e),
demonstrating similar performances compared to five other PPI
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detection methods (Fig. 2c) that averaged 20.4 ± 9.9% (S.D.) PRS
recovery (Fig. 3e, shaded blue area). When these 12 N2H versions
were combined, a PRS detection of 60% was yielded (Fig. 3f and
Supplementary Fig. 5a), similar to the 65% obtained by
combining either 10 different, version-limited assays from the
literature23–28 (Fig. 2a, b) or five non-N2H, multi-version assays
(Fig. 2c and Supplementary Fig. 5b).
These results highlight the advantages of using a single, highly
versatile PPI detection tool, such as N2H, to reduce the overall
cloning efforts and lab resources (Fig. 4a–c), as the same set of
expression vectors are used to explore several assay versions at a
time (Fig. 4d) whilst recovering as many PPIs as a combination of
many different techniques (Fig. 4e). The published assays in Fig. 4
are presented in Fig. 2a and Supplementary Table 1.
Combining multi-version assays to maximize PPI detection.
With all assays in hand to systematically evaluate the impact of
the three variables presented in Fig. 1b, we decided to combine
the different PPI assay versions previously tested against the
improved reference sets (Figs. 2c, 3e) with respect to each indi-
vidual parameter. All analyses were conducted in conditions
where none of the random pairs are scored positive.
As the impact of permuting proteins X and Y from one tag to
the other (Tag1-X:Tag2-Y vs. Tag1-Y:Tag2-X) had already been
comprehensively investigated by six different assays in the
literature23,26,27 (Supplementary Table 1), we only repeated
Y2H and MAPPIT to explore this parameter. While a single,
randomly picked orientation yielded PRS recovery rates of 19%
and 32%, switching to the second orientation increased detection
to 25% and 40% for Y2H and MAPPIT, respectively. Importantly,
cumulative PPI detection increased from 38% to 47% when a
single or two orientations were combined for both assays,
respectively (Fig. 5a). This 1.2-fold (47/38) increase was
consistent with our analysis of published results23,26,27 (Supple-
mentary Fig. 3a) and confirmed that permuting the orientation of
tested proteins is a valuable option to increase PPI detection.
To probe the influence of different tagging configurations on
PPI detection, i.e. the N- or C-terminal positioning of the assay
tags, we systematically evaluated the contribution of each pairing
combination (N1N2, C1N2, N1C2, and C1C2) with KISS,
NanoBiT, GPCA, mN2H, yN2H, and vN2H. For KISS, the
analysis was restricted to the two published configurations: N1N2
and C1N225. Using mN2H as a first example, we observed an
average PRS detection rate of 19% for a single, randomly picked
tagging configuration (Fig. 5b). When two of the four possible
Fig. 3 Development of the highly versatile N2H assay. a Determination of a new split site for NanoLuc. Dark blue bar and red arrow indicate the selected
NanoLuc fragments. RLU relative luminescence units, NLuc NanoLuc. Blank control corresponds to reagents without any NanoLuc fragment. (b) Tripartite
promoter and specific activities of selected N2H fragments, F1 and F2, normalized to full-length NanoLuc when expressed in mammalian cells (mN2H;
orange), in yeast (yN2H; purple), or in vitro (vN2H; gray), from the same plasmid. For “empty”: no protein or fragment was expressed. CMV
cytomegalovirus, HSV-TK herpes simplex virus-thymidine kinase, UAS upstream activating sequence, IRES internal ribosome entry site. Red arrow
displayed on NanoLuc structure (PDB: 5IBO) indicates the cleavage area. c Reproducibility of N2H assay in three expression environments (mN2H, yN2H,
and vN2H) for the N1N2 tagging configuration. Each triangle in the different graphs represents a single tested protein pair. d Normalized luminescence
signals for 12 versions of N2H benchmarked against hsPRS-v2 and hsRRS-v2. Blue squares and purple circles indicate PRS and RRS pairs, respectively. The
threshold of no RRS pair scoring positive is indicated (horizontal line) for each assay version. e Fraction of hsPRS-v2 pairs recovered by 12 N2H assay
versions when none of the hsRRS-v2 pairs are scored positive, corresponding to the thresholds displayed in (d). Horizontal shaded blue area indicates the
average recovery rate ± S.D. for all assay versions reported in Fig. 2c. f Cumulative hsPRS-v2 recovery rates when versions of N2H presented in (e) are
combined (individual data points are displayed in Supplementary Fig. 5a). Error bars indicate standard deviations (b, f) or standard errors of proportions (e)
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Fig. 4 Invested resources for various combinations of binary PPI assays and PRS detection rates. Numbers of (a) assays, (b) plasmids, (c) clonings per pair,
and (d) tested versions required to achieve the PRS recovery rates presented in (e). PRS recovery rates presented in Fig. 4e correspond to those found in
Fig. 2b (published), Supplementary Fig. 5b (non-N2H) and Fig. 3f (N2H). Except for Y2H-N1C2, Y2H-C1C2, and Y2H-C1N2 for which unambiguous
titrations could not be obtained from the original study28, all published assay versions benchmarked against hsPRS-v1 and hsRRS-v1 were used (Fig. 2a,
Supplementary Table 1)
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tagging configurations were used, the PRS recovery rate was
further increased to 28%. Finally, when three and all four tagging
configurations were combined, 34 and 37% of hsPRS-v2 pairs
were identified (Fig. 5b). Thus, using more than one tagging
configuration substantially increased the detection of binary PPIs
by mN2H. Similar observations were made for the other assays as
the PRS recovery rates were increased from an average 26% to
42% for KISS, where only two configurations were tested, and
from 14% to 28% for NanoBiT, 19% to 35% for GPCA, 21% to
45% for yN2H and 19% to 33% for vN2H when only one or all
four configurations were tested, respectively. The same trend was
observed when combining all tested versions and a 1.6-fold
increase in PRS detection obtained by extending assays from a
single to multiple configurations (Fig. 5b, union). These results
illustrate the gain of sensitivity achieved when performing the
same assay with different combinations of tagging configurations,
and confirm the preliminary observations made after reanalyzing
published data23,25 (Supplementary Fig. 3b).
To evaluate the impact of different protein expression systems
on binary PPI detection, we implemented different versions of the
N2H assay in yeast, in mammalian cells and in vitro (cell-free).
All four tagging configurations (Fig. 1b, c) were systematically
tested in each environment. For the N1N2 version, an average
PRS detection rate of 24% was reached when performing the
assay in a single environment. This recovery was increased to 35%
when switching to a second expression environment. Finally, after
combining detected PRS pairs from all three environments, the
cumulative recovery rate reached 42% for the N1N2 versions of
N2H (Fig. 5c). When we expanded the analysis to the other
tagging configurations, N1C2, C1C2, and C1N2, we consistently
observed that performing the assay with different expression
systems allowed the identification of a larger fraction of PPIs
(Fig. 5c). Indeed, a robust growth of cumulative PRS detection
was observed for N1C2 (from 18 to 40%), C1C2 (from 11 to
22%), and C1N2 (from 24 to 43%) when PPIs were tested in just
one or all three different expression environments, respectively.
Importantly, the cumulative PPI recovery rate for all 12 N2H
assay versions tested here was increased from 38% to 60% when
using one or all three expression systems, respectively, which
represented an overall 1.6-fold increase in PPI detection (Fig. 5c,
union). This result also highlights that the performance of the
single multi-version N2H assay (60% PRS recovery) was
significantly higher than that of any other method presented in
this study (Fig. 2a, c).
Taken together, these observations demonstrate the benefit of
permuting experimental conditions in binary PPI assays to
increase detection (Fig. 5a-c). What remained unclear was the
overall complementarity of assay versions when they are all
combined. To visualize the different subsets of interactions
recovered by the six different assays analyzed in this study
(Figs. 2c, 3e), we displayed the performance of their correspond-
ing 26 assay versions in the form of a checkerboard plot. Under
conditions where none of the hsRRS-v2 pairs are scored positive,
the different versions detected distinct but partially overlapping
subsets of PPIs, the union of which reached 78% (Fig. 6).
Importantly, as already observed in Fig. 3f, the combination of 12
N2H versions detected 60% of PRS pairs, which means that this
single assay recovered over three-quarters of all PPIs detected in
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ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11809-2
8 NATURE COMMUNICATIONS |         (2019) 10:3907 | https://doi.org/10.1038/s41467-019-11809-2 | www.nature.com/naturecommunications
this study (Fig. 6). Taken together, these results showed that a
single assay exploring multiple dimensions of the parameter space
(Fig. 1b, c) will be sufficient to map a large fraction of binary PPIs
in a defined search space.
Discussion
Over the past 10 years, the community has continuously released
new binary PPI detection tools. The benchmarking of these
assays, using a first generation of positive (hsPRS-v1) and random
(hsRRS-v1) reference sets, revealed that they often identify dis-
tinct subsets of interactions23. Therefore, a combination of mul-
tiple techniques will be required to increase overall PPI detection
and reach completeness (Fig. 1a). Under conditions of optimal
specificity, we have shown that no single PPI assay is excep-
tionally superior to any other, including the most recently
developed technologies. Furthermore, we have established that
instead of continuously developing fundamentally different
techniques, it should be possible to reach completeness by
assembling a minimal number of binary PPI assays, as long as
different experimental conditions, or assay versions, can be
implemented for each selected assay (Fig. 1b, c).
We eliminated the possibility that the failure of 10 combined
assays to detect about a third of known interactions in the original
hsPRSv122 came from ORF clone quality issues or problematic
interaction annotations by benchmarking assays against an
improved, unbiased second-generation of reference sets: hsPRS-
v2 and hsRRS-v2. Although the improvement of reference sets
was purely focused on pair quality in this study, the next gen-
eration of PRS and RRS should include larger fractions of inter-
actions such as those involved in higher order complex structures
as well as interactions from co-complex crystal structures where
direct contacts are well defined. Protein pairs for which a variety
of KD measurements are available27 will also be included to
characterize assays and assay versions according to their cap-
abilities of recovering interactions of different strengths.
Using the improved standards under conditions that max-
imized specificity, we have shown that considering three experi-
mental parameters, i.e. protein orientation, tagging configuration
and expression system (Fig. 1b), for assay development is a
valuable option to increase PPI detection. In particular, we
demonstrated that combining a relatively small number of assays
exploring these parameters could lead to a PPI detection rate of
up to 78%. In this context, we showed that combining 12 different
versions of N2H, a new, highly versatile split NanoLuc-based
assay, could recover 60% of all positive control interactions,
similar to the 65% recovery rates obtained by combining either 10
published version-limited assays or five distinct multi-version
assays. This means that the highly versatile N2H assay identified
77% of all PPIs detected in this study. In short, our results
highlight the advantage of N2H or similar versatile systems,
capable of handling several experimental parameters in a single,
multi-version toolkit, to improve PPI detection and ultimately
reduce the number of binary PPI assays required. This also
suggests that only a few versatile binary PPI assays will be suffi-
cient to reach complete coverage of any defined search space.
Surprisingly, 22% of hsPRS-v2 pairs remained undetected after
combining the six assays tested in this study, even though all
interactions had similar numbers of experimental evidence and
publications (Supplementary Fig. 6). We examined whether there
was any correlation between a tested PPI assay in this study, and
the original detection methods45 of the PRS pairs, but we did not
find any correlation between these two elements. In two cases, the
ORFs we used corresponded to shorter isoforms that did not
contain reported interaction domains (Supplementary Table 5).
Upon removal of these two ORFs, the PRS recovery rate by the
union of all 26 assay versions yields 81%. However, two thirds of
undetected hsPRS-v2 pairs contained reported interaction
domains. Therefore, to reach completeness, we suggest that future
assay development should be focused on expanding the number
of versions covered by already-existing techniques. In that regard,
we have extended our finding to the recently developed LuTHy
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Fig. 6 Complementarity of different assay versions. Detection of individual hsPRS-v2 pairs (left panel) by the assay versions used in Fig. 5a–c, under
conditions where none of the hsRRS-v2 pairs (right panel) are scored positive. Detected hsPRS-v2 pairs are indicated by blue squares: light blue
corresponds to individual assay versions and dark blue to the union of assay versions into distinct assays or combinations of assays. Identity of pairs can be
found in Supplementary Table 4
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assay27 and validated our original conclusions as additional PRS
detection was observed when running all 16 versions (2 envir-
onments × 2 orientations × 4 configurations) allowed by this
technology (data not shown). In addition, exploring yet untou-
ched experimental parameters such as additional modifications of
tag-protein fusions, or alternative expression environments
including sub-cellular localization should also help reaching full
coverage.
Given the difficulties of performing heterogeneous PPI assays
with the necessity of preparing different clones for expression
vectors and setting up different experiments, performing an equal
number of N2H assay versions to acquire comparable PPI
detection offers a valuable alternative to reduce these efforts
(Fig. 4a–e).
The fact that expression environment has a strong impact on
PPI detection is particularly interesting as it can easily be tuned
with N2H or similar versatile assays. For example, protein pairs
could be expressed in multiple cell lines, including distinct cell
types and tissue origins, while a range of pH or salt concentra-
tions could easily be tested when performing the assay in vitro.
From a single set of plasmids, this would open access to almost
unlimited assay versions to generate near-complete, high-quality
binary interactome maps in a more time-effective manner.
Methods
Processing publicly available hsPRS-v1 and hsRRS-v1 data. Publicly available
protein interaction datasets used in this study came from the original
publications23,24,26 or were provided by the authors upon request25,27. Analyses
were restricted to datasets for which a straightforward titration at a threshold of no
RRS pair scoring positive could be applied. To evaluate the recovery rates of hsPRS-
v1 when none of the RRS pairs are scored positive, data were calibrated such that
the provided score for a given PRS pair must be strictly higher than the highest
score of any of the RRS pairs. When authors clearly identified a particular pair as
not interacting (negative) in their experiments, this assignment was also considered
to generate the final dataset at a threshold where no RRS pair was scored positive.
The same criterion was applied to evaluate the fractions of pairs found with
available assay permutations, by using the highest RRS score found in each inde-
pendent version of the corresponding assay.
Construction of hsPRS-v2 and hsRRS-v2 reference sets. Second-generation
hsPRS-v2 (60 pairs) and hsRRS-v2 (78 pairs) were constructed from pre-existing
hsPRS-v1 (92 pairs) and hsRRS-v1 (92 pairs)23. To update the v1 sets generated
over 10 years ago, we first decided to obtain single colony isolates for each ORF
clone, removing all possible mutations that could have appeared in the original
mini-pool ORFeome collection11,46. Each entry clone passed through multiple
rounds of individual single colony isolations, plasmid DNA purifications, and
Sanger DNA sequencings, and only full-length, fully sequence-verified clones (next
generation sequencing) were selected. By comparing the ORF sequences with
genome annotations, we removed ORFs that did not match annotations in Gen-
code 2747, resulting in 76 PRS pairs and 78 RRS pairs (91.8% success rate at the
ORF level, Supplementary Fig. 2a). We further inspected the remaining 76 PRS
pairs by literature mining and informatics filtering. We revisited the supporting
evidence for each PRS pair using an updated classification of binary PPI detection
methods (Supplementary Data 1). For example, pull down and co-
immunoprecipitation are no longer considered as binary PPI detection methods12.
Ten PRS pairs not satisfying binary classification were removed. Three PRS pairs
containing HLA proteins were also discarded, as no reference ORF could be
defined. Finally, three PRS pairs between precursor ligands (FGF1, CXCL1, and
TNFSF10) and their respective receptors were also removed due to the requirement
of proteolytic cleavages of the ligands for maturation (Supplementary Table 2,
Supplementary Fig. 2b). After applying these filters, at total of 60 PRS pairs and 78
RRS pairs were thus assembled into hsPRS-v2 and hsRRS-v2, respectively (Sup-
plementary Table 4). Discarded pairs from hsPRS-v1 and hsRRS-v1 are presented
in Supplementary Data 1, and PubMed IDs supporting remaining hsPRS-v2 pairs
are presented in Supplementary Data 2. The performances of the updated reference
sets were compared to the older sets by repeating four assays previously bench-
marked with hsPRS-v1 and hsRRS-v1 (Supplementary Fig. 2c).
Cloning ORFs into Gateway-compatible expression plasmids. Human hsPRS-
v2 and hsRRS-v2 ORFs are available in pDONR221 or pDONR223 vectors, which
make them compatible with the Gateway-cloning technology. Each ORF was
introduced into the different assay-specific expression vectors used in this study via
an LR clonase-mediated Gateway reaction (Life Technologies). LR reaction pro-
ducts were subsequently transformed into DH5α competent bacterial cells and
grown for 24 h in ampicillin-containing TFB liquid medium. Plasmid DNA was
extracted using a NucleoSpin 96 Plasmid kit from Macherey-Nagel. After PCR-
amplification using plasmid-specific primers, the size of each DNA amplicon was
examined by agarose gel electrophoresis. For each batch of ready-to-go destination
vectors, DNA sequencing was performed on a subset of the cloned samples to
check the quality of cloning before running the PPI assays.
Construction of the tripartite promoter and N2H plasmids. The design of the 3-
in-1 hybrid promoter was based on the recent description of highly potent,
minimal synthetic promoters in yeast S. cerevisiae48. These promoters comprise a
short synthetic upstream activating sequence (UAS) and generic core elements,
including a TATA box and a Transcription Start Site (TSS). The average distance
separating the UAS motif upstream of the TATA box in native yeast and mam-
malian cell promoters was sufficient to insert the GC boxes and the CCAAT box-
binding transcription factor (CTF) binding site of the herpes simplex virus-
thymidine kinase (HSV-TK) promoter49 between these two elements. To boost
expression levels in mammalian cells, the cytomegalovirus (CMV) immediate early
enhancer was inserted upstream of the yeast synthetic UAS. To drive expression
in vitro using a coupled transcription/translation system, a T7 promoter was
inserted 30 nucleotides downstream of the TATA box, immediately followed by a
cricket paralysis virus internal ribosome entry site (CrPV-IRES), a versatile IRES
used to initiate translation in both, mammalian and yeast cells50,51. All these
regulatory elements were assembled using gene synthesis (GenScript) and 40
nucleotides of sequence homology to the insertion sites in the vector backbone
(pESC-LEU, Agilent, cat #217452; pESC-TRP, Agilent, cat #217453) were added for
gap repair recombination in yeast52,53. NanoLuc fragments, F1 (1–65) and F2
(66–171), were linked to either the N-terminal (pDEST-N2H-N1, -N2) or C-
terminal (pDEST-N2H-C1, -C2) extremity of the tested protein, using a flexible
hinge encoding a polypeptide of 20 amino acids along with Gateway recombina-
tional cloning sites. Finally, expression levels in the different systems were assessed
using full length or fragmented NanoLuc (Promega, cat #N1001) reporter genes
(Fig. 3b).
Systematic evaluation of NanoLuc fragments complementation. NanoLuc
fragments were systematically generated by transposon-based insertional muta-
genesis randomly distributed between nucleotides 55 and 249 of the NanoLuc
coding sequence, corresponding to amino acid residues 19 and 83, respectively
(Supplementary Fig. 4a). Resulting moieties were characterized by Sanger DNA
sequencing using pMOD forward and reverse primers according to the manu-
facturer’s protocol (EZ-Tn5, epicenter-Illumina, #TNP10622). Each fragment was
then subcloned into a specifically designed SNAP-Tag in vitro expression vector,
using Gateway recombination cloning (Life Technologies). They were expressed
using a human in vitro transcription/translation (IVT) system and their com-
plementation was assessed using a proximity-based assay.
Design of the SNAP-Tag in vitro expression vector. DNA encoding the SNAP-
Tag was PCR-amplified from the pSNAPf vector (NEBs, #N9183S) to be inserted in
frame into the pT7CFE1-CHis plasmid provided in the human IVT kit (Ther-
moFisher, #88882). The Gateway-cloning cassette was introduced immediately
after the SNAP-tag sequence using the Gateway vector conversion system (Invi-
trogen, #11828–029). All subsequent cloning steps were performed using Gateway
BP and LR reactions according to the manufacturer’s protocol. DNA constructs
were prepared using standard maxi- and mini-prep protocols.
Human IVT in vitro expression system. To assess complementation of NanoLuc
fragments, a HeLa cell lysate was used for in vitro coupled transcription and
translation (IVT system, ThermoFisher, #88882). All the reactions were performed
according to the manufacturer’s protocol, except for DNA concentrations (150 ng
for both expression vectors were used) and the use of a 5× dilution of the HeLa cell
lysate in the DB buffer. Concentrated DB buffer (10×) consisted in 540 mM
HEPES-KOH pH: 7.6; 800 mM K-acetate; 40 mM Mg-acetate; 50 mM DTT; 5 mM
Spermidine; 12.5 mM ATP and 200 mM Creatine phosphate. The final mixture
containing the diluted HeLa cell lysate with the accessory proteins and the man-
ufacturer’s reaction buffer was supplemented with 0.8 mM UTP, CTP; 1.2 mM
GTP, and 50 µM of each amino acid (Promega, #L446A). T7 RNA polymerase
(NEBs, #MO251L) were added at a final concentration of 1 unit/µL. Reaction was
performed for 90 min at 30 °C, directly in 96 or 384-well plates.
In vitro proximity assay based on SNAP-tag capture. NanoLuc fragments fused
to SNAP-tags were expressed in the human IVT system and assayed for com-
plementation by generating a Biotin–Streptavidin complex. After IVT expression,
the reaction mixture was incubated for 30 min at 30 °C with 1 µL/well of a 250 µM
SNAP-biotin substrate dilution in fresh DMSO. Streptavidin–biotin complexes
were further generated by adding 1 µL/well of 1 mg/mL of streptavidin solution
(Sigma-Aldrich, #85878). The reconstituted luciferase enzymatic activity was
monitored by injecting 50 µL/well of the Nano-Glo reagent (Promega, #N1120).
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Mammalian cell-based version of N2H assay (mN2H). HEK293T cells were
seeded at 6x104 cells per well in 96-well, flat-bottom, cell culture microplates
(Greiner Bio-One, #655083), and cultured in Dulbeccoʼs modified Eagleʼs medium
(DMEM) supplemented with 10% fetal calf serum at 37 °C and 5% CO2. Twenty-
four hour later, cells were transfected with 100 ng of each N2H plasmid (pDEST-
N2H-N1, -N2, -C1 or -C2) using linear polyethylenimine (PEI) to co-express the
protein pairs fused with complementary NanoLuc fragments, F1 and F2. The
DNA/PEI ratio used for transfection was 1:3 (mass:mass). Twenty-four hour after
transfection, the culture medium was removed and 50 μL of 100× diluted NanoLuc
substrate (Promega, #N1110) was added to each well of a 96-well microplate
containing the transfected cells. Plates were incubated for 3 min at room tem-
perature. Luciferase enzymatic activity was measured using a TriStar or CentroXS
luminometer (Berthold; 2 s integration time).
The stock solution of PEI HCl (PEI MAX 40000; Polysciences Inc; Cat# 24765)
was prepared according to the manufacturer’s instructions. Briefly, 200 mg of PEI
powder added to 170 mL of water, stirred until complete dissolution, and pH was
adjusted to 7 with 1 M NaOH. Water was added to obtain a final concentration of
1 mg/mL, and the stock solution was filtered through a 0.22 µm membrane.
Yeast cell-based version of N2H assay (yN2H). Using a high-efficiency LiAc/SS
carrier DNA/PEG protocol54, haploid S. cerevisiae Y8800 (MATa, leu2-3,112 trp1-
901, his3Δ200, ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::
LacZ@met2, GAL1::HIS3@LYS2) and Y8930 (MATα, leu2-3,112 trp1-901,
his3Δ200, ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::LacZ@-
met2, GAL1::HIS3@LYS2) yeast strains were transformed with pDEST-N2H
plasmids (pDEST-N2H-N1, -N2, -C1, and –C2) containing a TRP1 (N2/C2/
Fragment 2 vectors) or a LEU2 (N1/C1/Fragment 1 vectors) cassette, respectively.
For each individual transformation, 0.3 to 1.5 µg of high-purity plasmid and 1 mL
of log phase yeast cell culture (OD600 nm ~0.6–0.9) were used. The resulting
transformants carrying N2/C2/Fragment2 vectors (TRP1 cassette) or N1/C1/
Fragment1 vectors (LEU2 cassette) were spotted (8 µL per spot) onto solid syn-
thetic complete media lacking tryptophan (SC-W) or leucine (SC-L), respectively.
After 3 days of incubation at 30 °C, each transformant growing on solid SC-W or
SC-L was picked by scratching the corresponding spot and inoculated into a 96-
well microplate (Fisher Scientific/Corning, #07200720A) containing 160 µL of
liquid SC-W or SC-L per well, respectively. Inoculated yeast cells were incubated
overnight (15–18 h), at 30 °C and under shaking conditions (220 rpm). Haploid
yeast were mated by inoculating 5 µL of transformed MATa Y8800 and 5 µL of
transformed MATα Y8930 into a 96-well microplate containing 160 µL of YEPD
medium (yeast extract, peptone, dextrose) per well. Mating was obtained by
growing cells overnight (15–18 h), at 30 °C and under shaking conditions
(220 rpm). A first diploid selection was conducted by inoculating 10 µL of mated
yeast cells into a 96-well microplate containing 160 µL of SC-LW medium per well.
Cells were incubated overnight (15–18 h), at 30 °C and under shaking conditions
(220 rpm). A second diploid selection was conducted by inoculating 50 µL from the
first diploid selection culture into a 96-well deep well plate (QIAGEN, #19579)
containing 1.2 mL of liquid SC-LW medium per well. Diploids were grown by
incubating cells for 24 h, at 30 °C and under shaking conditions (900 rpm). Cell
density was determined by transferring 100 µL of each diploid cell culture into
individual wells of a 96-well microplate and measuring OD600 nm with a microplate
reader (optional). Deep well plates containing diploid yeast cells were centrifuged
at 2,500 g for 15 min. After centrifugation, the supernatant was discarded and
residual SC-LW medium removed by gently blotting deep well plates with absor-
bent paper. Each yeast cell pellet was individually resuspended into 100 µL of the
NanoLuc Assay solution by gently pipetting up-and-down several times, until cell
pellets were fully dispersed. Homogenized solutions were transferred into white
flat-bottom 96-well plates (Greiner bio-one, cat# 655073) that were then sealed
with aluminum foil and incubated for 1 h at room temperature. After incubation,
plates were shaken for 30 s at 950 rpm to resuspend yeast cells. Using a lumin-
ometer (Berthold) set up for one-second orbital shaking before each measurement
(speed: fast; diameter: 5 mm), luminescence was evaluated for each reaction.
Integration time of the luminescence signal was set at 2 s per sample.
In vitro version of N2H assay (vN2H). Synthesis of proteins was performed
separately using the in vitro coupled transcription–translation system based on
Insect Cell Extract (ICE) (TnT-T7-ICE, Promega, #L1102). In this ICE coupled
transcription–translation system, transcription is driven by T7 RNA-Polymerase
present in the ICE reagent. The necessary T7 promoter is included in the N2H
synthetic promoter as described in Fig. 3b. Each reaction was performed in 25 µL
final volume with 1 µg of pDEST-N2H plasmid (5 µL at 200 ng/µL) and 20 µL of
diluted insect cell extract (containing 4 µL of ICE, 3.2 µL of 5× ICB dilution buffer
and eight units of T7-RNAP-Promega#P4074, supplemented with H2O up to
20 µL). Incubation was at 30 °C for 4 h. The synthesis reaction was stopped by
addition of 50 µL of 1× PBS (Gibco, #14190–094) containing 20% glycerol (for
storage at −80 °C). The NanoLuc assay was carried out in 96-well format by mixing
5 µL of each in vitro synthesized protein with 15 µL of 1× PBS per well. After
incubation at 30 °C for 90 min, 50 µL of 100× diluted NanoLuc substrate (Promega,
#N1110) were added, and luciferase enzymatic activity was measured using a
TriStar or CentroXS luminometer (Berthold; 5 s integration time).
Concentrated insect cell buffer (ICB 5×) consists of 150 mM HEPES-KOH pH:
7.6; 750 mM K-acetate; 19.5 mM Mg-acetate; 12.5 mM DTT; 500 µM spermidine;
100 mM creatine phosphate; 0.5 mg/mL creatinine kinase; 8.75 mM ATP; 1.5 mM
GTP, CTP, UTP and 500 µM amino acids mix. The stock solution of amino acids
(3.4 mM) was made by dissolving the 20 powders into 5 M KOH, at concentrations
ranging from 1.6 to 4M. The resulting mixtures containing each of the 20 amino
acids were diluted in water to achieve a final concentration of 238 mM. The final
aqueous solution was adjusted to pH 7.5 with acetic acid, diluted to 3.4 mM and
frozen in liquid nitrogen for storage at −80 °C.
Yeast 2-Hybrid (Y2H) assay. Using a high-efficiency LiAc/SS carrier DNA/PEG
protocol54, haploid S. cerevisiae Y8800 (MATa, leu2-3,112 trp1-901, his3Δ200,
ade2-101 ura3-52, gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::LacZ@met2, GAL1::
HIS3@LYS2) and Y8930 (MATα, leu2-3,112 trp1-901, his3Δ200, ade2-101 ura3-52,
gal4Δ, gal80Δ, chy2R, GAL2::ADE2, GAL7::LacZ@met2, GAL1::HIS3@LYS2) yeast
strains were transformed with pDEST-AD and pDEST-DB plasmids16 containing a
TRP1 or a LEU2 cassette, respectively. For auto-activation tests (DB-X/Y vs. AD-
empty), Y8800 (MATa) yeast cells were also transformed with a pDEST-AD-empty
plasmid. Six standard Y2H controls were also transformed into yeast cells: (1)
pDEST-AD-empty/pDEST-DB-empty, (2) pDEST-AD-CBLB/pDEST-DB-GRB2,
(3) pDEST-AD-XIAP/pDEST-DB-CASP9, (4) pDEST-AD-empty/pDEST-DB-
scGal4, (5) pDEST-AD-empty/pDEST-DB-WDR62, and (6) pDEST-AD-scUme6
(a.a. 531-a.a. 836)/pDEST-DB. For each individual transformation, 0.3–1.5 µg of
high-purity plasmid and 1 mL of a log phase-growth yeast cell culture (OD600 nm
~0.6–0.9) were used. The resulting transformants carrying pDEST-AD vectors
(TRP1 cassette) or pDEST-DB vectors (LEU2 cassette) were spotted (8 µL per spot)
onto solid synthetic complete media lacking tryptophan (SC-W) or leucine (SC-L),
respectively. After 3 days of incubation at 30 °C, each transformant growing on
solid SC-W or SC-L was picked by scratching the corresponding spot, and
inoculated into a 96-well costar plate (Fisher Scientific/Corning, #07200720A)
containing 160 µL of liquid SC-W or SC-L per well, respectively. Inoculated yeast
cells were incubated overnight (15–18 h), at 30 °C and under shaking conditions
(220 rpm). Haploid yeast were mated by inoculating 5 µL of transformed MATa
Y8800 and 5 µL of transformed MATα Y8930 into a 96-well microplate containing
160 µL of YEPD medium (yeast extract, peptone, dextrose) per well. The exact
same mating was done for the auto-activation tests (DB-X/Y-containing cells
mated with AD-empty-containing cells). Mating was obtained by growing cells
overnight (15–18 h), at 30 °C and under shaking conditions (220 rpm). The diploid
selection was conducted by inoculating 10 µL of mated yeast cells into a 96-well
microplate containing 160 µL of SC-LW medium per well. Cells were incubated
overnight (15–18 h), at 30 °C and under shaking conditions (220 rpm). Using a
liquid handling robot, each diploid cell culture was then spotted in quadruplicate
(1 μL/spot) onto two different solid media plates: (1) SC-LW, and (2) SC-LW
lacking histidine and containing 1 mM of 3-Amino-1,2,4-triazole (3-AT) (SC-
LWH, 1 mM 3-AT). The six controls described above were also spotted on each
solid plate to validate composition of selective media (based on their known
phenotypes on these media) and compare their growth rates to the ones of tested
protein pairs. Plates were incubated for 4 days at 30 °C and 2 days at room
temperature before evaluating growth scores.
Gaussia princeps complementation assay (GPCA). HEK293T cells were cultured
as described for the mN2H assay version. For each protein, 100 ng of purified
plasmid DNA was transfected into HEK293T cells in 96-well, flat-bottom, cell
culture plates (Greiner Bio-One, #655083) supplemented with 10%FBS in DMEM
using polyethylenimine24. The DNA/PEI ratio (mass:mass) was 1:3. GPCA vectors
carry the human cytomegalovirus (CMV) promoter and are maintained as high
copy number with the human virus SV40 replication origin in mammalian cells.
24 h after DNA transfection, the cell culture medium was removed, cells were gently
washed with 150 µL pre-warmed 1x PBS, 40 µL of lysis buffer was then added per
well, and cell lysis was performed under vigorous shaking of the plate for 20min at
900 rpm. Luminescence was measured by auto-injecting 50 µL Renilla luciferase
substrate (Renilla Luciferase Assay system, catalog No. E2820, Promega) per well
and integrating light output for 4 s using a TriStar luminometer (Berthold).
Construction of C-terminal plasmids for GPCA. GPCA C1 and C2 vectors are
based on two fragments of the humanized Gaussia princeps luciferase (herein
referred as GLuc), similar to the GPCA N1 and N2 vectors24. Both GLuc fragments
were linked to the C-terminal extremity of the tested proteins by a flexible hinge
polypeptide of 20 amino acids, including the Gateway recombinational cloning
sites. To normalize mRNA translation initiation, a consensus Kozak translation
start sequence was added. Both constructs were carried by the same CMV driven
mammalian expression vector (pCI-neo derived, Promega) and were maintained as
multi-copies within the cells via the presence of the SV40 replication origin.
NanoLuc® Binary Technology (NanoBiT) assay. HEK293T cells were cultured as
described for the mN2H assay version. For each protein, 100 ng of purified plasmid
DNA was transfected into HEK293T cells grown in 96-well, flat-bottom, cell cul-
ture microplates (Greiner Bio-One, #655083). The DNA/PEI ratio (mass:mass) was
1:3 for the transfection. 24 h later, 100 µL of the NanoLuc substrate (Promega,
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#N1110) were added to each well, plates were incubated for 3 min at room tem-
perature, and luminescence output was measured using a TriStar luminometer
(Berthold; 1 s integration time).
Construction of Gateway-compatible plasmids for NanoBiT. The Gateway
reading frame cassette was amplified by PCR, and polished with a PCR polishing
kit (Agilent, # 200409) to generate blunt-end DNA. NanoBiT vectors (Promega, #
N2014) with N- and C-terminus tagging configurations (NB MCS1, NB MCS2, NB
MCS3, NB MCS4) were obtained from Promega, each containing an HSV-TK
promoter for protein expression in mammalian cells and an ampicillin resistance
marker for bacterial selection of transformed cells. Each plasmid DNA for
NanoBiT vectors (NB MCS1-4) was digested with a single-cut restriction enzyme
(EcoRI for NB MCS1 and 2, and SacI for NB MCS3 and 4) at the multiple cloning
sites (MCS). The linearized plasmid DNA was processed with the PCR polishing kit
generating blunt-end DNA. Antarctic phosphatase (NEB, M0289S) was used to
remove 5′-phosphates to reduce self-ligation background of the linearized vector.
The ligation reaction was performed with T4 DNA ligase (NEB, M0202S) joining
the linearized NanoBiT vectors (NB MCS1-4) with the polished Gateway reading
frame cassette. The ligated, Gateway-compatible NanoBiT vectors (NanoBiT-GW-
N1, -N2, -C1 and –C2) were introduced into One ShotTM ccdB survivalTM 2 T1R
competent E. coli cells (Invitrogen, #A10460) via heat shock bacterial transfor-
mation, and selected on chloramphenicol-containing LB agar plates. The sequences
of constructed NanoBiT-GW vectors were examined by Sanger DNA sequencing.
The final vectors contained correct sequences of the promoter, NanoBiT fragments,
junctions, and Gateway cassette.
MAPPIT and KISS assays. HEK293T cells were cultured as described for the
mN2H assay version. In both Mammalian protein–protein interaction trap
(MAPPIT) and Kinase substrate sensor (KISS assays)12,25, HEK293T cells were
transfected with bait, prey and reporter plasmids applying a standard calcium
phosphate transfection method. Luciferase activity was measured 48 h after
transfection using the Luciferase Assay System kit (Promega) on a Enspire
luminometer (Perkin-Elmer). For MAPPIT, half of the cells were stimulated with
erythropoietin (2 ng/mL; GenScript) 24 h after transfection. For each tested pair in
MAPPIT, the fold-induction value (signal from two stimulated culture wells
divided by the signal from two unstimulated culture wells) was calculated. For KISS
the average of four culture wells was used.
Scoring hsPRS-v2 pairs. Data for each assay version performed in this study are
presented in Source Data. All binary PPI experiments were independently per-
formed three times. For the different versions of N2H experiments, the average
signal of the three replicates was used to determine a raw luminescence value for
each protein pair X/Y. Control experiments were performed similarly where pro-
tein X or Y fused to the NanoLuc fragment F1 or F2 was co-expressed with the
matching NanoLuc fragment alone (X/empty or empty/Y). For each protein pair
X–Y, we calculated a normalized luminescence ratio (NLR) corresponding to the
raw luminescence value of the tested pair (X–Y) divided by the maximum lumi-
nescence value from one of the two controls (X-empty or empty-Y), as summarized
in Eq. (1) 25:
NLRXY ¼
LuminescenceXY
MaximumLuminescenceðXemptyÞorðemptyYÞ
: ð1Þ
To identify protein pairs that score positive at a threshold of no RRS detection,
two criteria were considered: (1) NLRPRS > NLRHIGHEST RRS and (2) NLRPRS > 1.0.
All PRS pairs that did not meet these two criteria were not scored and therefore
defined as not detectable in the corresponding assay version. The same analysis and
criteria were applied for both KISS and MAPPIT assays.
For GPCA and NanoBiT experiments, a PRS pair was scored positive if its
corresponding raw luminescence signal (from the average of three independent
experiments) was strictly higher than the RRS pair having the highest raw
luminescence signal (from the average of three independent experiments).
For Y2H assay, diploid yeast cells containing both, DB-X/Y bait and AD-Y/X
prey plasmids, were spotted in quadruplicate on selective medium supplemented
with 3-AT (SC-LWH, 3-AT). After titration of 3-AT, a minimal concentration of 1
mM was selected as no RRS pairs were detected for this specific threshold12. In
parallel, diploid yeast cells containing DB-X/Y bait and AD-empty prey vectors
were also used to identify bait proteins that are auto-activators of the HIS3 selection
marker. After 6 days of culture, yeast growth was visually determined and scored
from “0” (no growth) to “4” (strong growth) for both the DB-X/Y:AD-Y/X and
DB-X/Y:AD-empty combinations. If the growth score was >0 for the DB-X/Y:AD-
Y/X combination in at least two of the three experiments performed and was
superior by at least 2 units to the one of DB-X/Y:AD-empty combination, a protein
pair was scored positive.
Construction of cumulative recovery plots. To plot the fraction of interaction
recovered for n number of assays or assay versions, the recovery rate for each of the
possible n combinations was calculated first (Supplementary Figs. 1c, 2d, 5a) and
then averaged (Figs. 2b, d, 3f and Supplementary Fig. 5b). The error bars in Figs.
2b, d, 3f and Supplementary Fig. 5b indicate the standard deviation of the average.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the findings from this study are included either in the manuscript
and its associated supplementary files, or can be extracted from the original referenced
publications. The protein–protein interaction data have been deposited to the IntAct
database (https://www.ebi.ac.uk/intact/), and will be publicly available with PubMed ID
upon publication. All data are also available from the authors upon request. N2H
plasmids and their corresponding maps were deposited to the Addgene plasmid
repository (https://www.addgene.org/Marc_Vidal/).
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